Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 7, 2017, Pages 1448-1452

  Peyvandi, F ^a   Scully, M ^b   Kremer Hovinga, J A ^c   Knobl P ^d   Cataland, S ^e   De Beuf, K ^f   Callewaert, F ^f   De Winter, H ^f   Zeldin, R K ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e OHIO STATE UNIVERSITY   (United States)

^f ABLYNX NV   (Belgium)

Author keywords

caplacizumab; morbidity; mortality; purpura, thrombotic thrombocytopenic; von Willebrand factor

Indexed keywords

CAPLACIZUMAB; PLACEBO; ADAMTS13 PROTEIN, HUMAN; FIBRINOLYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NANOBODY; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADULT; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; PATIENT SAFETY; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM; TREATMENT OUTCOME; YOUNG ADULT;

ADAMTS13 PROTEIN; ADULT; AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT SAFETY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-BLIND METHOD; SINGLE-DOMAIN ANTIBODIES; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 85020192555     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13716     Document Type: Article

References (20)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060–9.
2. Sadler JE. von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11–18.
3. Goel R, King KE, Takemoto CM, Ness PM, Tobian AA. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion 2016; 56: 1451–8.
4. Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125: 1470–6.
5. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500–11. Quiz 662.
6. Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provot F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 2012; 97: 1181–6.
7. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323–35.
8. Veyradier A. von Willebrand factor – a new target for TTP treatment? N Engl J Med 2016; 374: 583–5.
9. Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 511–22.
10. Peyvandi F, Callewaert F. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 2497–8.
11. Morgand M, Buffet M, Busson M, Loiseau P, Malot S, Amokrane K, Fortier C, London J, Bonmarchand G, Wynckel A, Provot F, Poullin P, Vanhille P, Presne C, Bordessoule D, Girault S, Delmas Y, Hamidou M, Mousson C, Vigneau C, et al. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion 2014; 54: 389–97.
12. Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provot F, Maury E, Pene F, Mira JP, Wynckel A, Presne C, Poullin P, Halimi JM, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 2015; 13: 293–302.
13. Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010; 89: 1029–33.
14. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood 2015; 125: 3860–7.
15. Hughes PA. Comprehensive care of adults with acute ischemic stroke. Crit Care Nurs Clin North Am 2011; 23: 661–75.
16. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129: 1493–501.
17. Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, Perdue JJ, Terrell DR, Vesely SK, George JN. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 2015; 90: 709–14.
18. Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013; 122: 2023–9. Quiz 142.
19. Kennedy AS, Lewis QF, Scott JG, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 1092–101.
20. Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 118–24.